{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:37:12Z","timestamp":1786995432443,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,20]],"date-time":"2020-12-20T00:00:00Z","timestamp":1608422400000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.parkreldis.2019.12.011","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T19:57:29Z","timestamp":1576612649000},"page":"55-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6545-196X","authenticated-orcid":false,"given":"Sibylle","family":"de Germay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2019.12.011_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1472-8206.1994.tb00808.x","article-title":"Drug-induced parkinsonism: a review","volume":"8","author":"Montastruc","year":"1994","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.parkreldis.2019.12.011_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2515\/therapie:2004021","article-title":"Drug-induced Parkinson syndromes","volume":"59","author":"Nguyen","year":"2004","journal-title":"Therapie"},{"key":"10.1016\/j.parkreldis.2019.12.011_bib3","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/mds.23828","article-title":"Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France","volume":"26","author":"Bondon-Guitton","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.12.011_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/mds.26839","article-title":"Incidence and time trends of drug-induced parkinsonism: a 30-year population-based study","volume":"32","author":"Savica","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.12.011_bib5","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.parkreldis.2019.12.011_bib6","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40266-018-0590-y","article-title":"Current methods for the treatment and prevention of drug-induced parkinsonism and tardive dyskinesia in the elderly","volume":"35","author":"Estevez-Fraga","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.parkreldis.2019.12.011_bib7","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson's disease: a systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2019.12.011_bib8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson's disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"GBD 2016 Neurology collaborators","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2019.12.011_bib9","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000445751","article-title":"The incidence of Parkinson's disease: a systematic review and meta-analysis","volume":"46","author":"Hirsch","year":"2016","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.parkreldis.2019.12.011_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.therap.2016.02.029","article-title":"French pharmacovigilance: missions, organization and perspectives","volume":"71","author":"Vial","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.parkreldis.2019.12.011_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.therap.2016.02.008","article-title":"Pharmacovigilance in Europe: place of the pharmacovigilance risk assessment committee (PRAC) in organisation and decisional processes","volume":"71","author":"Laroche","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.parkreldis.2019.12.011_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1472-8206.2007.00552.x","article-title":"The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database","volume":"22","author":"Bate","year":"2008","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.parkreldis.2019.12.011_bib13","author":"UMC"},{"key":"10.1016\/j.parkreldis.2019.12.011_bib14","author":"MedDRA"},{"key":"10.1016\/j.parkreldis.2019.12.011_bib15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"10.1016\/j.parkreldis.2019.12.011_bib16","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00228-018-2496-3","article-title":"Tamoxifen and the risk of Parkinsonism: a case\/non-case study","volume":"74","author":"Montastruc","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.parkreldis.2019.12.011_bib18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.parkreldis.2019.12.011_bib19","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.parkreldis.2019.12.011_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.therap.2017.08.006","article-title":"Case-non case studies: principles, methods, bias and interpretation","volume":"73","author":"Faillie","year":"2018","journal-title":"Therapie"},{"key":"10.1016\/j.parkreldis.2019.12.011_bib21","first-page":"1142","article-title":"ISoP18-1110 Who's at risk? identifying risk groups for adverse drug reactions using Vigibase","volume":"41","author":"Aoki","year":"2018","journal-title":"Drug Saf."},{"key":"10.1016\/j.parkreldis.2019.12.011_bib22","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1176\/appi.ps.004662012","article-title":"Diffusion of antipsychotics in the US and French markets, 1998-2008","volume":"64","author":"Gallini","year":"2013","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.parkreldis.2019.12.011_bib23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2188\/jea.JE20081034","article-title":"Systematic review of the prevalence and incidence of Parkinson's disease in Asia","volume":"19","author":"Muangpaisan","year":"2009","journal-title":"J. Epidemiol."},{"key":"10.1016\/j.parkreldis.2019.12.011_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mdc3.12568","article-title":"Epidemiology of Parkinson's disease-east versus west","volume":"5","author":"Abbas","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.parkreldis.2019.12.011_bib25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/pgmj.2008.073312","article-title":"Drug induced parkinsonism: a common cause of parkinsonism in older people","volume":"85","author":"Thanvi","year":"2009","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.parkreldis.2019.12.011_bib26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40263-016-0341-8","article-title":"Valproate-associated parkinsonism: a critical review of the literature","volume":"30","author":"Brugger","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.parkreldis.2019.12.011_bib27","series-title":"Goodman and Gilman: the Pharmacological Basis of Therapeutics","first-page":"335","article-title":"5-hydroxytryptamine (serotonin) and dopamine","author":"Elaine","year":"2018"},{"key":"10.1016\/j.parkreldis.2019.12.011_bib28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions\u00a0: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.parkreldis.2019.12.011_bib29","series-title":"Advances in Inflammatory Research","first-page":"1","article-title":"Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs","author":"Weber","year":"1984"},{"key":"10.1016\/j.parkreldis.2019.12.011_bib30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00002826-199510000-00004","article-title":"Effects of calcium antagonists on the dopamine system","volume":"18","author":"Mena","year":"1995","journal-title":"Clin. Neuropharmacol."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019305309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019305309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:18:27Z","timestamp":1761178707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802019305309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":29,"alternative-id":["S1353802019305309"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.12.011","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}